Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FER | P16591 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 8/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 5/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848843 | 1.00 | FER (0.41) | FERIGF1RFAAHCYP3A4CYP1A2 | |
| SCHEMBL1158096 | 0.93 | IGF1R (0.46) | FERIGF1RCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1158088 | 0.93 | IGF1R (0.46) | FERIGF1RCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1158759 | 0.93 | IGF1R (0.46) | FERIGF1RCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1158623 | 0.87 | SYK (0.39) | FERIGF1RKARS1ZAP70SYK | |
| SCHEMBL1158567 | 0.87 | SYK (0.39) | FERIGF1RKARS1ZAP70SYK | |
| SCHEMBL1158677 | 0.85 | SYK (0.40) | FERIGF1RKARS1ZAP70SYK | |
| SCHEMBL1158652 | 0.82 | FER (0.41) | FERIGF1RKARS1ZAP70SYK | |
| SCHEMBL1158729 | 0.81 | KARS1 (0.49) | FERIGF1RKARS1ZAP70SYK | |
| SCHEMBL12848848 | 0.80 | FER (0.40) | FERIGF1RKARS1ZAP70SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | FER 89/4885IGF1R 1151/4885FAAH 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.